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had restrictive cardiomyopathy with cardiogenic shock and DCM
secondary to cobalt poisoning. Classiﬁcation of degree of heart
failure prior to LVAD was done as per INTERMACS score and 7
patients were classiﬁed at INTERMACS category 2, 3 patients in
INTERMACS category 3 and one in INTERMACS 4. 2 patients were
on prior ECMO support and 8 were on inotropes prior to LVAD
implant. 3 patients had high creatininemore than 2 and 3 had high
bilirubin and altered LIVER function. In all patients ECHO derived
RV function, RV stroke works index and pulmonary vascular resis-
tance were measures carefully. RV function parameters include
TAPSE, mean area change of RV and S' by tissue Doppler. PVR
calculated by cardiac catheterization with cardiac output mea-
sured by thermodilution catheter.
Results: 9 patients were discharged successfully from the hospital.
There was one hospital mortality due to sepsis and intracerebral
hemorrhage. And another due to severe right heart failure and liver
failure. All patients were put on oral anticoagulants (Warfarin). All
the 9 discharged patients were assessed every 2months post LVAD
with pump interrogation, echocardiography and clinician's judg-
ment of Quality of life (Minnesota QOLI) and PT/INR. All patients
reported a good to excellent improvement. 7 patients are doing
well with good pump parameters and no signs of heart failure after
a minimum of 4 months andmaximum of 3 years follow-up There
was one late mortality 18 months post LVAD due to fulminant
hepatic failure. There was no incidence of CVA or signiﬁcant aortic
leak.
Conclusion: LV assist devices can be safely implanted in terminally
ill heart failure patients. Good patient selection, adequate patient
optimization before implant and timing of intervention are the key
to successful outcomes. Meticulous assessment and management
of RV function and strict anticoagulation regimen plays a crucial
role.
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Peadatric heart transplantation poses huge challenges especially in
developing country like India. A common challenge for sick chil-
dren with severe, end stage heart failure is paucity of donors of
similar weight, because child heart donors are rare in India.
Because of this problem some of the strategies employed by
transplant teams is usage of oversized donors up to 2 times body
weight and also utilizing ABO incompatible donors. Here we report
our unique experience in 2 children aged 13 years (HK,
weight = 37 kg) and 10 years (BJ, weight = 25 kg), both of whom
needed oversized donors.
We report 2 children suffering from end stage heart failure due to
dilated cardiomyopathy. Preoperatively, they were in INTERMACS
Grade 3–4 CHF and on intermittant IV milrinone infusion. Creati-
nine levels 1.8–2 mg/dl and bilirubin levels 2 mg and 2.7 mg/dl.
Cardiac cath showed PVR of 4 and 4.2 Wood units respectively.
They were transplanted with donor hearts of 65 kg and 50 kg
respectively. On the 2–3rd postoperative day, both patients had
seizures (right focal in one and generalized in other) followed by
reduced consciousness levels. BP was noted to be persistently
above 150/90 in the ﬁrst 2 days although they were on one inotrope
(isoprenaline). The problemwas recognized as Big Heart Syndrome
and appropriate action take to reduce cerebral hyperperfusion and
reactive vasoconstriction with BP lowering using small doses of
nifedipine and NTG and slow tapering of inotrope. Both patients
recovered completely over next 8–10 days.
Big Heart Syndrome, a well described entity in countries with large
transplant programmes but not so commonly known in India. This
syndrome has been described when donor hearts are oversized.
This procedure is deemed suboptimal but becomes extremely
essential when recipient is sick because of heart failure and same
size donors are unavailable. This is a common problem in coun-
tries with Inadequate Organ Sharing and Donation programmes in
children with end stage heart failure below body weight of 35 kg.
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We studied 36 patients who underwent heart transplant in our
center between 2011 and 2014 who had elevated creatinine more
than 1. 8 mg/dl and creatinine clearance less than 40 ml/min and
who were selected for a induction therapy using modiﬁed immu-
nosuppressive regime with the CD 25 inhibitor basilixmab (simu-
lect) – different from International protocols using antithymocyte
globulin or OK T3.
Patient proﬁle – Age range 10–66 years, weight range – 34–70 kg,
creatinine range 1.8–2.6 mg/dl. All patients were NYHA class 3 and
above, 24 were in NYHA class 4 (severe CHF) and 16 were in
INTERMACS grade 3 and below.
Almost all had raised JVP with pedal edema, 20 had ascites and 26
had albumin less than 3 mg/dl.
LV EF 12–30%, 34 had moderate to severe RV dysfunction.
Cardiac cath done in all – RA mean = 18–24 mmHg, PA mean = 28–
40 mmHg PVR range = 2.1–4.5 Wood units. A total of 5 patients had
PVR more than 4 (labile with milrinone and nitric oxide).
All patients were put on IV milrinone infusion for 5–7 days before
heart transplant which reduced RA mean by average of 8 mmHg,
PVR by 2.3 WU, improved NYHA class by 1 grade and improved
urine output and Appetite. A total of 2 patients were tested with
inhaled NO with up to 18 mm fall in PA mean pressure.
Just before heart transplant, all patients received 10–20mg of basi-
liximab (dose as per bodyweight and general condition) single dose.
Post operatively in 26 patients creatinine levels normalized by day 5,
allowing initiation of tacrolimus. In other 10 patients tacrolimus
couldbestartedonlyatday10withno ill effectsor rejectionepisodes.
In all patients CD 25 level was checked on day 3 and second dose of
simulect given only of CD 25 more than 3%. Post op no patient had
sustained neutropenia. Only 2 patients needed therapy for azotemia
with post operative dialysis. A total of 1 patient died of severe RF and
sepsis. Advantages of induction therapy using basiliximab will be
discussedalongwithpathophysiologyofazotemia insevereCHFand
reversal of cardiorenal syndrome using milrinone.
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